Nintedanib Teva B.V. (Nintedanib)

The drug blocks several receptor tyrosine kinases—VEGFR, PDGFR and FGFR—thereby reducing fibroblast activation, angiogenesis and extracellular matrix formation. This inhibition curtails the fibrotic process in the lungs and can also limit tumor‑driven vascular development when used with other anticancer agents.

The prescribed dose of Nintedanib is determined by the treating physician based on the specific indication, patient characteristics and tolerability. Dosage regimens are not standardized in public literature and should always follow the prescriber’s instructions.

Safety data for Nintedanib in pregnancy and lactation are insufficient, and the product is classified as having an unknown pregnancy category. It is generally avoided in pregnant or nursing women unless the potential benefit outweighs the potential risk, as decided by a qualified healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

The primary alternative for idiopathic pulmonary fibrosis is pirfenidone, another antifibrotic agent. While both slow disease progression, Nintedanib targets a broader range of tyrosine‑kinase receptors, which may provide additional benefit in systemic sclerosis‑associated lung disease and certain cancer regimens. Safety profiles differ, with Nintedanib more frequently causing gastrointestinal side effects and pirfenidone associated with photosensitivity.

Nintedanib should be stored at temperatures below 25 °C, in its original packaging to protect it from moisture and light. Keep the product in a dry place and avoid exposure to excessive heat or humidity to maintain its stability throughout its shelf life.

The medication is taken orally, usually as a tablet, with food or a light meal to reduce gastrointestinal irritation. Patients should swallow the tablet whole with water and follow the dosing schedule prescribed by their healthcare provider.

Serious adverse events include severe liver injury, arterial thromboembolic events such as heart attack or stroke, major bleeding, gastrointestinal perforation, and significant hypertension. Patients should be monitored regularly for signs of these conditions, and therapy should be discontinued if any serious reaction occurs.

Nintedanib is contraindicated in patients with severe hepatic impairment, active bleeding disorders, recent major cardiovascular events, and in women who are pregnant or may become pregnant without effective contraception. It should also be used with caution in individuals with moderate renal impairment or a history of gastrointestinal ulcers.